AR101269A1 - CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33 - Google Patents

CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33

Info

Publication number
AR101269A1
AR101269A1 ARP150102311A ARP150102311A AR101269A1 AR 101269 A1 AR101269 A1 AR 101269A1 AR P150102311 A ARP150102311 A AR P150102311A AR P150102311 A ARP150102311 A AR P150102311A AR 101269 A1 AR101269 A1 AR 101269A1
Authority
AR
Argentina
Prior art keywords
car
heavy chain
domain
complementarity determining
determining region
Prior art date
Application number
ARP150102311A
Other languages
Spanish (es)
Inventor
Zhang Jiquan
Wu Qilong
Song Huijuan
Singh Reshma
Richardson Celeste
Murphy Leon
C Milone Michael
Mannick Joan
Kenderian Saad
Jascur Julia
Huber Thomas
Glass David
Gill Saar
Ebersbach Hilmar
Brogdon Jennifer
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag
Publication of AR101269A1 publication Critical patent/AR101269A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La solicitud proporciona composiciones y métodos para el tratamiento de enfermedades asociadas con la expresión de CD33. La solicitud se refiere también a receptor quimérico antígeno (CAR) específico para CD33, los vectores que codifican al mismo, y las células T recombinantes que comprenden el CAR CD33. La solicitud también incluye métodos de administración de una célula T modificada genéticamente que expresa un CAR que comprende un dominio de unión a CD33. Reivindicación 1: Una molécula aislada de ácido nucleico que codifica un receptor quimérico de antígeno (CAR), en donde el CAR comprende un dominio de unión a CD33 humano, un dominio de transmembrana, y un dominio de señalización intracelular y en donde dicho dominio de unión a CD33 comprende una región determinante de complementariedad de cadena pesada 1 (HC CDR1), una región una región determinante de complementariedad de cadena pesada 2 (HC CDR2) y una región determinante de complementariedad de cadena pesada 3 (HC CDR3) de cualquiera de las secuencias de aminoácidos de dominio de unión a cadena pesada CD33 enumeradas en la Tabla 2 ó 9.The application provides compositions and methods for the treatment of diseases associated with the expression of CD33. The application also refers to chimeric antigen receptor (CAR) specific for CD33, the vectors encoding it, and the recombinant T cells comprising the CD33 CAR. The application also includes methods of administration of a genetically modified T cell expressing a CAR comprising a CD33 binding domain. Claim 1: An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a human CD33 binding domain, a transmembrane domain, and an intracellular signaling domain and wherein said domain of CD33 binding comprises a heavy chain complementarity determining region 1 (HC CDR1), a region a heavy chain complementarity determining region 2 (HC CDR2) and a heavy chain complementarity determining region 3 (HC CDR3) of any of the CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9.

ARP150102311A 2014-07-21 2015-07-21 CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33 AR101269A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014082589 2014-07-21

Publications (1)

Publication Number Publication Date
AR101269A1 true AR101269A1 (en) 2016-12-07

Family

ID=58699641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102311A AR101269A1 (en) 2014-07-21 2015-07-21 CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33

Country Status (1)

Country Link
AR (1) AR101269A1 (en)

Similar Documents

Publication Publication Date Title
AR101829A1 (en) CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER
CO2017000507A2 (en) Chimeric bcma antigen receptor
AR125268A2 (en) OPTIMIZATION OF ANTIBODIES THAT BIND TO THE LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND THEIR USES
MX2019006340A (en) Anti-ctla-4 antibodies and methods of use thereof.
JOP20210076A1 (en) Bispecific t cell engaging antibody constructs
MX2023000818A (en) Anti-ctla-4 antibodies and methods of use thereof.
CY1119760T1 (en) USE OF MODIFICATION OF CELLS MODIFIED BY CHEMICAL ANTIGON CELL RECEPTORS FOR CANCER TREATMENT
GEP20237528B (en) Antibodies against signal-regulatory protein alpha and methods of use
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MY195089A (en) Anti-Tim-3 Antibodies and Methods of use thereof
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
MX2022005955A (en) Methods and compositions for adoptive cell therapy.
MX2020001450A (en) Methods and compositions for reducing immunosupression by tumor cells.
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
MX2018005618A (en) Chimeric receptors containing traf-inducing domains and related compositions and methods.
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
AR102698A1 (en) ANTIBODIES AGAINST CD73 AND ITS USES
PE20171654A1 (en) COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY
AR101669A1 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
WO2015138600A3 (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
PE20141908A1 (en) CD47 ANTIBODIES AND METHODS OF USE THEM
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
AR109683A1 (en) ANTIBODIES AGAINST FACTOR XI AND ITS USES
EA202091567A1 (en) CHIMERIC PROTEINS MIT